Drug discovery company Argent BioPharma (ASX: RGT) (LSE: RGT) (OTCQB: RGTLF) on Monday announced a strategic collaboration with SINTEF, a large European independent research organisation, to tackle the clinical challenge of chronic wound management.
This partnership aims to develop nano-formulations that address antibiotic-resistant infections and deteriorating tissue health, marking Argent BioPharma's expansion into new therapeutic areas.
The collaboration will focus on identifying novel antimicrobial agents and enhancing their effectiveness through nano-formulation technology. These formulations are designed to improve drug delivery, penetrate biofilms and provide sustained release, addressing the complexities of chronic wounds.
Argent BioPharma will fund the project and retain ownership of all intellectual property generated.
This initiative aligns with Argent BioPharma's broader strategy of developing multidisciplinary, nano-based therapies, particularly in the central nervous system and immunology sectors.
Vesper Bio announces positive Phase I results for FTD treatment
Telix Pharmaceuticals submits TLX101-CDx NDA to US FDA
Argent BioPharma partners with SINTEF to advance chronic wound management
NRx Pharmaceuticals and HOPE Therapeutics align with FDA on Pediatric Study Plan for NRX-100
TPG invests in K2 Medical Research to expand clinical trial site platform
Amneal announces launch of PEMRYDI RTU, a ready-to-use oncology injectable
Lipocine doses first cohort in LPCN 1154 study
BenevolentAI reports positive Phase Ia safety and pharmacokinetic data for BEN-8744
AstraZeneca announces US approval for Ultomiris for NMOSD treatment
GenSight Biologics declares efficacy and safety of LUMEVOQ four years post-injection
Nuvalent's NVL-520 receives FDA breakthrough therapy designation
Nuvalent commences NVL-655 phase 2 clinical trial in subjects with NSCLC and other solid tumours